# LifePlanOS CTO / Clinical AI Audit

**Repository reviewed:** `LifePlanOS-review(1).zip`  
**Audit date:** 2026-07-12  
**Scope:** architecture, clinical-evidence integrity, Standard of Care, Evidence Explorer, testing, security, and commercial readiness.

## Executive conclusion

LifePlanOS has progressed from an early prototype to a credible early-stage vertical SaaS platform. The repository now contains a structured case model, recommendation lifecycle, persisted validation findings, an evidence graph, version comparison, role-specific review views, rate limiting, storage cleanup, and a substantial test suite.

The most important remaining risk is **clinical evidence quality**, not interface design. The current system can still attach the same article or guideline to multiple diagnoses or recommendations because relevance is primarily determined by token, region, and service matching. The Evidence Explorer then faithfully displays those stored links, but it does not independently verify whether each source is actually the best available evidence for the selected diagnosis or recommendation.

The product is suitable for continued internal testing and controlled design-partner evaluation after the evidence-quality work below. It is not yet ready for unsupervised production use in medicolegal reports.

## Current maturity score

| Area | Score | Assessment |
|---|---:|---|
| Product direction | 9.5/10 | Clear vertical focus and strong workflow thesis. |
| Architecture | 8.8/10 | Coherent Next.js/Prisma design with improving domain structure. |
| Multi-tenancy / auditability | 8.5/10 | Good direction; automated tenant tests are present. |
| Recommendation lifecycle | 8.8/10 | Supersede-not-delete and transition history materially improve defensibility. |
| Report generation | 8.4/10 | Strong professional output; accuracy remains dependent on upstream evidence quality. |
| Standard of Care evidence | 6.5/10 | Real-source retrieval and verbatim quotes are strengths; clinical applicability and source hierarchy need stricter controls. |
| Evidence Explorer | 6.8/10 | Good provenance UI, but it displays what is stored rather than independently validating the quality and uniqueness of that evidence. |
| Test discipline | 8.6/10 | 157 tests passed; three unhandled Prisma-engine initialization errors occurred in this Linux audit environment. |
| Commercial readiness | 7.2/10 | Strong foundation for design partners; evidence QA and operational hardening remain launch gates. |

## Highest-priority findings

### Critical 1 — Source reuse can create false clinical relevance

The recommendation literature engine lightly penalizes reuse but does not prohibit the same article from supporting several clinically distinct diagnoses or services. A paper may therefore remain the top-ranked result across multiple items when the candidate pool is weak.

**Required correction:** source assignment must be diagnosis- and question-specific, with a hard applicability gate and a source-use policy. Reuse should be allowed only when a source genuinely addresses each selected clinical question.

### Critical 2 — Evidence Explorer is a provenance viewer, not yet an evidence-quality engine

The Evidence Explorer combines recommendation literature with inherited diagnosis evidence and guidelines. This is useful, but it does not show:

- why each article was selected;
- evidence level;
- population applicability;
- intervention and outcome match;
- whether a stronger guideline or systematic review was searched for;
- contradictory literature;
- uncertainty caused by missing patient facts;
- whether the article is duplicated elsewhere in the case.

**Required correction:** create a structured evidence assessment for every source and clinical claim.

### High 1 — Standard of Care can over-interpret abstract language

The Standard of Care engine correctly tries to locate actual guidelines, excludes obvious “guideline-about-guidelines” studies, and quotes retrieved language. However, matching guideline text to documented care is still based largely on extracted significant terms. This can imply that a broad guideline point is “addressed” merely because a related term appears in a chronology event or planned-care service.

**Required correction:** separate guideline discovery, recommendation extraction, patient applicability, and care-concordance mapping into explicit reviewed steps.

### High 2 — Standard of Care source hierarchy is incomplete

The retrieval layer merges Europe PMC, Crossref, and Semantic Scholar. That improves coverage, but authoritative society and government guidelines should outrank generic indexed literature. The system should preferentially locate primary guideline publishers and verify the source is the current version.

### High 3 — Contrary evidence is underdeveloped

The Evidence Explorer's “What weakens it” section mainly surfaces `opposingRecords` from the condition. It does not systematically retrieve high-quality conflicting literature, identify negative tests, alternative diagnoses, natural-history uncertainty, treatment-response evidence, or absence of treating-physician support.

### High 4 — “Unknown” content is too dependent on one free-text field

For a condition, unknowns come from `missingInfo`; for a recommendation, from `missingSupport`. This is insufficient for a thorough review. Unknowns should be composed from a structured gap model covering clinical, functional, temporal, coding, pricing, causation, physician-support, and evidence-quality gaps.

## Launch recommendation

Proceed to a targeted **Clinical Evidence Quality Epic** before adding more visible features. This Epic should make Standard of Care and Evidence Explorer the most trustworthy parts of the product.
